Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, January 19, 2022
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
[ Wed, Jan 19th 2022
] - WOPRAI
Tue, January 18, 2022
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
[ Tue, Jan 18th 2022
] - WOPRAI
David Lebowitz Maintained (ALNY) at Buy with Decreased Target to $215 on, Jan 18th, 2022
David Lebowitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Decreased Target from $226 to $215 on, Jan 18th, 2022.
David has made no other calls on ALNY in the last 4 months.
There are 8 other peers that have a rating on ALNY. Out of the 8 peers that are also analyzing ALNY, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Mani Foroohar of "SVB Leerink" Maintained at Hold with Increased Target to $108 on, Thursday, October 28th, 2021
These are the ratings of the 7 analyists that currently disagree with David
- Edward Tenthoff of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $208 on, Monday, January 3rd, 2022
- Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $205 on, Monday, November 22nd, 2021
- Luca Issi of "RBC Capital" Upgraded from Hold to Buy and Increased Target to $225 on, Monday, November 22nd, 2021
- Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Held Target at $273 on, Monday, November 22nd, 2021
- Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $200 on, Monday, November 1st, 2021
- Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $200 on, Friday, October 29th, 2021
- Esther Rajavelu of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $215 on, Monday, October 4th, 2021
